Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 0.67 |
| ▸ | RARG | P13631 | 9/20 | 0.67 |
| ▸ | RARA | P10276 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.67 |
| ▸ | GOT1 | P17174 | 1/20 | 0.67 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827566 | 0.90 | HDAC11 (0.68) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL15216914 | 0.88 | RARB (0.64) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL178043 | 0.87 | RARA (0.58) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL4542585 | 0.85 | RARB (0.63) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL4539864 | 0.85 | RARB (0.60) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL4542588 | 0.85 | RARB (0.63) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL17322459 | 0.85 | RARB (0.65) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL5827886 | 0.84 | RARB (0.70) | RARBRARGRARAMEN1KMT2A | |
| Adapalene SCHEMBL21724750 | 0.83 | RARB (0.83) | RARBRARGRARAMEN1KMT2A | |
| SCHEMBL641031 | 0.83 | RARB (0.67) | RARBRARGRARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | RARB 3380/4885RARG 3697/4885RARA 3491/4885 |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | RARB 1465/4885RARG 1374/4885RARA 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.